Histone lysine demethylases as targets for anticancer therapy

Nature Reviews Drug Discovery

Volumn 12, Issue 12, 2013, Pages 917-930

  Højfeldt, Jonas W ^a,b   Agger, Karl ^a,b   Helin, Kristian ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; F BOX AND LEUCINE RICH REPEAT PROTEIN 10; F BOX PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE INHIBITOR; JMJC DEMETHYLASE INHIBITOR; PROTEIN JARID1B; PROTEIN JMJD2; PROTEIN LSD1; PROTEIN LSD1 INHIBITOR; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CHROMATIN STRUCTURE; COLORECTAL CANCER; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE MUTATION; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; KIDNEY CARCINOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEMETHYLASES; HUMANS; NEOPLASMS;

EID: 84889573275     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4154     Document Type: Review

References (191)

1. You, J. S. & Jones, P. A. Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22, 9-20 (2012
2. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet. 44, 251-253 (2012
3. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - Biological and translational implications. Nature Rev. Cancer 11, 726-734 (2011
4. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012
5. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: A new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384-400 (2012
6. Wigle, T. J. & Copeland, R. A. Drugging the human methylome: An emerging modality for reversible control of aberrant gene transcription. Curr. Opin. Chem. Biol. 17, 369-378 (2013
7. Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-599 (2000
8. Black, J. C., Van Rechem, C. & Whetstine, J. R. Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol. Cell 48, 491-507 (2012
9. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011
10. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011
11. Varambally, S. et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002
12. Bracken, A. P. et al. EZH2 is downstream of the pRB E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003
13. Hudlebusch, H. R. et al. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res. 71, 4226-4235 (2011
14. Wang, P. et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1 mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29, 6074-6085 (2009
15. Dorrance, A. M. et al. The Mll partial tandem duplication: Differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood 112, 2508-2511 (2008
16. Dorrance, A. M. et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Invest. 116, 2707-2716 (2006
17. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005
18. Albert, M. & Helin, K. Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21, 209-220 (2010
19. Greer, E. L. & Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nature Rev. Genet. 13, 343-357 (2012
20. Peters, A. H. et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323-337 (2001
21. Jiang, H. et al. Role for Dpy 30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell 144, 513-525 (2011
22. Pasini, D., Bracken, A. P., Jensen, M. R., Lazzerini Denchi, E. & Helin, K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23, 4061-4071 (2004
23. Margueron, R. et al. Role of the Polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762-767 (2009
24. Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120-124 (2001
25. Kouzarides, T. SnapShot: Histone-modifying enzymes. Cell 131, 822 (2007
26. Yun, M., Wu, J., Workman, J. L. & Li, B. Readers of histone modifications. Cell Res. 21, 564-578 (2011
27. Zhang, Z. & Pugh, B. F. High-resolution genome-wide mapping of the primary structure of chromatin. Cell 144, 175-186 (2011
28. Henikoff, S. & Shilatifard, A. Histone modification: Cause or cog? Trends Genet. 27, 389-396 (2011
29. Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953 (2004
30. Tsukada, Y. i. et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439, 811-816 (2006
31. Whetstine, J. R. et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125, 467-481 (2006
32. Klose, R. J. et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442, 312-316 (2006
33. Cloos, P. A. C. et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442, 307-311 (2006
34. Fodor, B. D. et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 20, 1557-1562 (2006
35. Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nature Rev. Mol. Cell Biol. 13, 297-311 (2012
36. Zee, B. M. et al. In vivo residue-specific histone methylation dynamics. J. Biol. Chem. 285, 3341-3350 (2010
37. Barth, T. K. & Imhof, A. Fast signals and slow marks: The dynamics of histone modifications. Trends Biochem. Sci. 35, 618-626 (2010
38. Karytinos, A. et al. A novel mammalian flavin-dependent histone demethylase. J. Biol. Chem. 284, 17775-17782 (2009
39. Fitzpatrick, P. F. Oxidation of amines by flavoproteins. Arch. Biochem. Biophys. 493, 13-25 (2010
40. Aravind, L. & Iyer, L. M. The SWIRM domain: A conserved module found in chromosomal proteins points to novel chromatin-modifying activities. Genome Biol. 3, research0039 (2002
41. Forneris, F., Binda, C., Vanoni, M. A., Mattevi, A. & Battaglioli, E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett. 579, 2203-2207 (2005
42. Chen, Y. et al. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc. Natl Acad. Sci. USA 103, 13956-13961 (2006
43. Forneris, F., Binda, C., Adamo, A., Battaglioli, E. & Mattevi, A. Structural basis of LSD1 CoREST selectivity in histone H3 recognition. J. Biol. Chem. 282, 20070-20074 (2007
44. Fang, R. et al. LSD2/KDM1B and its cofactor NPAC/ GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Mol. Cell 49, 558-570 (2013
45. Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436-439 (2005
46. Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108 (2007
47. Kontaki, H. & Talianidis, I. Lysine methylation regulates E2F1 induced cell death. Mol. Cell 39, 152-160 (2010
48. Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nature Genet. 41, 125-129 (2009
49. Yoneyama, M. et al. Structural and functional differences of SWIRM domain subtypes. J. Mol. Biol. 369, 222-238 (2007
50. Chen, F. et al. Structural insight into substrate recognition by histone demethylase LSD2/KDM1b. Cell Res. 23, 306-309 (2013
51. Zhang, Q. et al. Structure-function analysis reveals a novel mechanism for regulation of histone demethylase LSD2/AOF1/KDM1b. Cell Res. 23, 225-241 (2013
52. Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432-435 (2005
53. Shi, Y. J. et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19, 857-864 (2005
54. Yang, M. et al. Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol. Cell 23, 377-387 (2006
55. Hausinger, R. P. FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit. Rev. Biochem. Mol. Biol. 39, 21-68 (2004
56. McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J. & Schofield, C. J. Structural studies on human 2 oxoglutarate dependent oxygenases. Curr. Opin. Struct. Biol. 20, 659-672 (2010
57. Iyer, L. M., Abhiman, S., de Souza, R. F. & Aravind, L. Origin and evolution of peptide-modifying dioxygenases and identification of the wybutosine hydroxylase/hydroperoxidase. Nucleic Acids Res. 38, 5261-5279 (2010
58. Hegg, E. L. & Que, L. The 2 His 1 carboxylate facial triad - an emerging structural motif in mononuclear non-heme iron(II) enzymes. Eur. J. Biochem. 250, 625-629 (1997
59. Klose, R. J., Kallin, E. M. & Zhang, Y. JmjC-domain-containing proteins and histone demethylation. Nature Rev. Genet. 7, 715-727 (2006
60. Horton, J. R., Upadhyay, A. K., Hashimoto, H., Zhang, X. & Cheng, X. Structural basis for human PHF2 Jumonji domain interaction with metal ions. J. Mol. Biol. 406, 1-8 (2011
61. Stender, J. D. et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol. Cell 48, 28-38 (2012
62. Wen, H. et al. Recognition of histone H3K4 trimethylation by the plant homeodomain of PHF2 modulates histone demethylation. J. Biol. Chem. 285, 9322-9326 (2010
63. Baba, A. et al. PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. Nature Cell Biol. 13, 668-675 (2011
64. Del Rizzo, P. A., Krishnan, S. & Trievel, R. C. Crystal structure and functional analysis of JMJD5 indicate an alternate specificity and function. Mol. Cell. Biol. 32, 4044-4052 (2012
65. Webby, C. J. et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 325, 90-93 (2009
66. Ng, S. S. et al. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 448, 87-91 (2007
67. Chen, Z. et al. Structural basis of the recognition of a methylated histone tail by JMJD2A. Proc. Natl Acad. Sci. USA 104, 10818-10823 (2007
68. Couture, J. F., Collazo, E., Ortiz-Tello, P. A., Brunzelle, J. S. & Trievel, R. C. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nature Struct. Mol. Biol. 14, 689-695 (2007
69. Krishnan, S. & Trievel, R. C. Structural and functional analysis of JMJD2D reveals molecular basis for site-specific demethylation among JMJD2 demethylases. Structure 21, 98-108 (2013
70. Horton, J. R. et al. Enzymatic and structural insights for substrate specificity of a family of Jumonji histone lysine demethylases. Nature Struct. Mol. Biol. 17, 38-43 (2010
71. Yan, J. et al. EZH2 overexpression in natural killer/T cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 121, 4512-4520 (2013
72. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012
73. Yan, L. et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO 2008 classification. Haematologica 97, 1708-1712 (2012
74. Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010
75. Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875-878 (2011
76. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521-523 (2009
77. Dalgliesh, G L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 463, 360-363 (2010
78. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin. Nature Genet. 42, 181-185 (2010
79. Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574-586 (2011
80. Kauffman, E. C. et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50, 931-944 (2011
81. Kahl, P. et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66, 11341-11347 (2006
82. Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012
83. Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Med. 18, 605-611 (2012
84. Oryzon Genomics S. A. Phenylcyclopropylamine derivatives and their medical use. WO2010084160A1 (2010
85. Yang, Z. Q. et al. Identification of a novel gene, GASC1, within an amplicon at 9p23 24 frequently detected in esophageal cancer cell lines. Cancer Res. 60, 4735-4739 (2000
86. Liu, G. et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28, 4491-4500 (2009
87. Ehrbrecht, A. et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208, 554-563 (2006
88. Shi, L. et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl Acad. Sci. USA 108, 7541-7546 (2011
89. Kawazu, M. et al. Histone demethylase JMJD2B functions as a co factor of estrogen receptor in breast cancer proliferation and mammary gland development. PloS ONE 6, e17830 (2011
90. Yang, J. et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 70, 6456-6466 (2010
91. Fu, L. et al. HIF 1α induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis 33, 1664-1673 (2012
92. Wissmann, M. et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nature Cell Biol. 9, 347-353 (2007
93. Rui, L. et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18, 590-605 (2010
94. Albert, M. et al. The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3. PLoS Genet. 9, e1003461 (2013
95. Schmitz, S. U. et al. Jarid1b targets genes regulating development and is involved in neural differentiation. EMBO J. 30, 4586-4600 (2011
96. Lu, P. J. et al. A novel gene (PLU 1) containing highly conserved putative DNA/chromatin binding motifs is specifically up regulated in breast cancer. J. Biol. Chem. 274, 15633-15645 (1999
97. Barrett, A. et al. PLU 1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/ testis antigen? Int. J. Cancer 101, 581-588 (2002
98. Hayami, S. et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: Involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol. Cancer 9, 59 (2010
99. Xiang, Y. et al. JARID1B is a histone H3 lysine 4 demethylase up regulated in prostate cancer. Proc. Natl Acad. Sci. USA 104, 19226-19231 (2007
100. Yamane, K. et al. PLU 1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25, 801-812 (2007
101. Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594 (2010
102. Wu, X., Johansen, J. V. & Helin, K. Fbxl10/Kdm2b recruits Polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. Mol. Cell 49, 1134-1146 (2013
103. He, J., Nguyen, A. T. & Zhang, Y. KDM2b/JHDM1b, an H3K36me2 specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117, 3869-3880 (2011
104. Tzatsos, A. et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J. Clin. Invest. 123, 727-739 (2013
105. Farcas, A. M. et al. KDM2B links the Polycomb repressive complex 1 (PRC1) to recognition of CpG islands. eLIFE 1, e00205 (2012
106. Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G. & Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13, 563-567 (2006
107. Schmidt, D. M. Z. & McCafferty, D. G. trans 2 phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46, 4408-4416 (2007
108. Yang, M. et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans 2 phenylcyclopropylamine. Biochemistry 46, 8058-8065 (2007
109. Shih, J. C., Chen, K. & Ridd, M. J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 22, 197-217 (1999
110. Ueda, R. et al. Identification of cell-active lysine specific demethylase 1 selective inhibitors. J. Am. Chem. Soc. 131, 17536-17537 (2009
111. Mimasu, S. et al. Structurally designed trans 2 phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49, 6494-6503 (2010
112. Neelamegam, R. et al. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem. Neurosci. 3, 120-128 (2012
113. Maes, T. et al. Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J. Clin. Oncol. Abstr. 31, e13543 (2013
114. Lohse, B. et al. Inhibitors of histone demethylases. Bioorg. Med. Chem. 19, 3625-3636 (2011
115. Huang, Y. et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl Acad. Sci. USA 104, 8023-8028 (2007
116. Huang, Y. et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 15, 7217-7228 (2009
117. Willmann, D. et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer 131, 2704-2709 (2012
118. Wang, J. et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 71, 7238-7249 (2011
119. Cain, C. AML takes LSD1. SciBx http://dx.doi. org/10.1038/scibx.2012.352 (2012
120. Fiskus, W. et al. Pre-clinical efficacy of combined therapy with LSD1 antagonist SP 2509 and pan-histone deacetylase inhibitor against AML blast progenitor cells. Abstract 868. 54th American Society of Hematology Annual Meeting and Exposition [online], https://ash.confex.com/ ash/2012/webprogram/ Paper53429.html (2012
121. Yu, V. et al. High-throughput TR FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases. J. Biomol. Screen 17, 27-38 (2012
122. Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064-15069 (2004
123. Rose, N. R. et al. Inhibitor scaffolds for 2 oxoglutarate-dependent histone lysine demethylases. J. Med. Chem. 51, 7053-7056 (2008
124. King, O. N. F. et al. Quantitative high-throughput screening identifies 8 hydroxyquinolines as cell-active histone demethylase inhibitors. PloS ONE 5, e15535 (2010
125. Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012
126. Liang, Y. et al. Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci. Transl. Med. 5, 167ra165 (2013
127. Wang, L. et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nature Commun. 4, 2035 (2013
128. Brien, G. L. et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nature Struct. Mol. Biol. 19, 1273-1281 (2012
129. Suzuki, C. et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol. Cancer Ther. 6, 542-551 (2007
130. Komiya, K. et al. Expression of Mina53, a novel c Myc target gene, is a favorable prognostic marker in early stage lung cancer. Lung Cancer 69, 232-238 (2010
131. Komiya, K. et al. Mina53, a novel c Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J. Cancer Res. Clin. Oncol. 136, 465-473 (2010
132. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
133. Humphrey, G. W. et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta L1. J. Biol. Chem. 276, 6817-6824 (2001
134. You, A., Tong, J. K., Grozinger, C. M. & Schreiber, S. L. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc. Natl Acad. Sci. USA 98, 1454-1458 (2001
135. Hakimi, M. A. et al. A core BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl Acad. Sci. USA 99, 7420-7425 (2002
136. Lee, M. G. et al. Functional interplay between histone demethylase and deacetylase enzymes. Mol. Cell. Biol. 26, 6395-6402 (2006
137. Lan, F. et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1 mediated gene repression. Nature 448, 718-722 (2007
138. Singh, M. M. et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-Oncol. 13, 894-903 (2011
139. Luger, K., Dechassa, M. L. & Tremethick, D. J. New insights into nucleosome and chromatin structure: An ordered state or a disordered affair? Nature Rev. Mol. Cell Biol. 13, 436-447 (2012
140. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41-45 (2000
141. Stavropoulos, P., Blobel, G. & Hoelz, A. Crystal structure and mechanism of human lysine-specific demethylase 1. Nature Struct. Mol. Biol. 13, 626-632 (2006
142. Kong, X. et al. Catalytic mechanism investigation of lysine-specific demethylase 1 (LSD1): A computational study. PloS ONE 6, e25444 (2011
143. Yu, T., Higashi, M., Cembran, A., Gao, J. & Truhlar, D. G. Concerted hydrogen atom and electron transfer mechanism for catalysis by lysine-specific demethylase. J. Phys. Chem. B 117, 8422-8429 (2013
144. Schulte, J. H. et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res. 69, 2065-2071 (2009
145. Lim, S. et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31, 512-520 (2010
146. Ciccone, D. N. et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 461, 415-418 (2009
147. Heidenblad, M. et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med. Genom. 1, 3 (2008
148. Okada, Y. et al. Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis. Nature 450, 119-123 (2007
149. Inagaki, T. et al. Obesity and metabolic syndrome in histone demethylase JHDM2a deficient mice. Genes Cells 14, 991-1001 (2009
150. Tateishi, K. et al. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 458, 757-761 (2009
151. Liu, Z. et al. Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis. J. Biol. Chem. 285, 2758-2770 (2010
152. Uemura, M. et al. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: In vivo identification from hypoxic tumor cells. Clin. Cancer Res. 6, 4636-4646 (2010
153. Qi, J. et al. Siah2 dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18, 23-38 (2010
154. Guo, X. et al. The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 58, 153-157 (2011
155. Yamada, D. et al. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: Clinical impact on recurrence after hepatic resection. Ann. Surg. Oncol. 19 (Suppl. 3) 355-364 (2011
156. Zhang, Q. J. et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Invest. 121, 2447-2456 (2011
157. Patani, N., Jiang, W. G., Newbold, R. F. & Mokbel, K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 31, 4115-4125 (2011
158. Pryor, J. G. et al. Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor. Am. J. Dermatopathol. 33, 780-785 (2011
159. Vinatzer, U. et al. Mucosa-associated lymphoid tissue lymphoma: Novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 14, 6426-6431 (2008
160. Iwamori, N., Zhao, M., Meistrich, M. L. & Matzuk, M. M. The testis-enriched histone demethylase, KDM4D, regulates methylation of histone H3 lysine 9 during spermatogenesis in the mouse but is dispensable for fertility. Biol. Reprod. 84, 1225-1234 (2011
161. Satoh, T. et al. The Jmjd3 Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nature Immunol. 11, 936-944 (2010
162. Agger, K. et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23, 1171-1176 (2009
163. Barradas, M. et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23, 1177-1182 (2009
164. Ciavatta, D. J. et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J. Clin. Invest. 120, 3209-3219 (2010
165. Anderton, J. A. et al. The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's lymphoma. Oncogene 30, 2037-2043 (2011
166. Cox, B. J. et al. Phenotypic annotation of the mouse X chromosome. Genome Res. 20, 1154-1164 (2010
167. Lee, S. et al. UTX, a histone H3 lysine 27 demethylase, acts as a critical switch to activate the cardiac developmental program. Dev. Cell 22, 25-37 (2012
168. Jankowska, A. M. et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118, 3932-3941 (2011
169. Lederer, D. et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am. J. Hum. Genet. 90, 119-124 (2012
170. Ishimura, A. et al. Jmjd5, an H3K36me2 histone demethylase, modulates embryonic cell proliferation through the regulation of Cdkn1a expression. Development 139, 749-759 (2012
171. Fukuda, T., Tokunaga, A., Sakamoto, R. & Yoshida, N. Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. Mol. Cell. Neurosci. 46, 614-624 (2011
172. Kottakis, F. et al. FGF 2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B miR 101 EZH2 pathway. Mol. Cell 43, 285-298 (2011
173. Sinha, S. et al. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma. Mol. Cancer 7, 84 (2008
174. Ghosh, A. et al. Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck. Ann. Surg. Oncol. 19 (Suppl. 3), 528-538 (2011
175. Laumonnier, F. et al. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J. Med. Genet. 42, 780-786 (2005
176. Abidi, F. E., Miano, M. G., Murray, J. C. & Schwartz, C. E. A novel mutation in the PHF8 gene is associated with X linked mental retardation with cleft lip/cleft palate. Clin. Genet. 72, 19-22 (2007
177. Koivisto, A. M. et al. Screening of mutations in the PHF8 gene and identification of a novel mutation in a Finnish family with XLMR and cleft lip/cleft palate. Clin. Genet. 72, 145-149 (2007
178. Klose, R. J. et al. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889-900 (2007
179. Vogt, T. et al. Deficiency of a novel retinoblastoma binding protein 2 homolog is a consistent feature of sporadic human melanoma skin cancer. Lab. Invest. 79, 1615-1627 (1999
180. van Zutven, L. J. C. M. et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 45, 437-446 (2006
181. Pointon, J. J. et al. The histone demethylase JARID1A is associated with susceptibility to ankylosing spondylitis. Genes Immun. 12, 395-398 (2011
182. Catchpole, S. et al. PLU 1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int. J. Oncol. 38, 1267-1277 (2011
183. Abidi, F. E. et al. Mutations in JARID1C are associated with X linked mental retardation, short stature and hyperreflexia. J. Med. Genet. 45, 787-793 (2008
184. Jensen, L. R. et al. Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X linked mental retardation. Am. J. Hum. Genet. 76, 227-236 (2005
185. Santos, C. et al. A novel mutation in JARID1C gene associated with mental retardation. Eur. J. Hum. Genet. 14, 583-586 (2006
186. Tzschach, A. et al. Novel JARID1C/SMCX mutations in patients with X linked mental retardation. Hum. Mutat. 27, 389 (2006
187. Jensen, L. R. et al. A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C. PathoGenetics 3, 2 (2010
188. Santos-Rebouças, C. B. et al. A novel nonsense mutation in KDM5C/JARID1C gene causing intellectual disability, short stature and speech delay. Neurosci. Lett. 498, 67-71 (2011
189. Adegbola, A., Gao, H., Sommer, S. & Browning, M. A novel mutation in JARID1C/SMCX in a patient with autism spectrum disorder (ASD). Am. J. Med. Genet. A 146A, 505-511 (2008
190. Perinchery, G. et al. Deletion of Y chromosome specific genes in human prostate cancer. J. Urol. 163, 1339-1342 (2000
191. Takeuchi, T. et al. Jumonji gene is essential for the neurulation and cardiac development of mouse embryos with a C3H/He background. Mechanisms Dev. 86, 29-38 (1999